Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, today announced the launch of its Xyralid® Suppositories, for the reduction of swelling or inflammation of hemorrhoidal tissues and provides pain relief from burning, itching and discomfort. Xyralid® Suppositories received a Product License Application (“PLA”) in Canada and the product is available as an over-the-counter (“OTC”) or behind the counter drug and will not require a prescription. The product is available in Canada directly through the Company’s website and through its Beyond Human® marketing and sales platform.
“We are very excited to announce the Health Canada approval and launch of our Xyralid® Suppositories product in Canada,” said Dr. Bassam Damaj, the President and Chief Executive Officer of Innovus Pharma. “Xyralid® Suppositories are being launched through our own sales and marketing commercial efforts there, and is our ninth product on the Canadian market, including Zestra®, Zestra Glide® and Uxor™ (EjectDelay®) marketed by Orimed Pharma and UriVarx® through our partnership with Acerus Pharmaceuticals Corporation and Vesele®, Apeaz®, Xyralid® Cream and ProstaGorx®. In addition, we have four other products: PEVarx®, Diabasens®, RecalMax® and BH Testosterone™, that have been submitted and are being reviewed currently by Health Canada for potential approval.”